Pub Date : 2020-02-13DOI: 10.15406/ppij.2020.08.00280
P. Lutgen, Jérôme Munyangi, Pascal Gisenya, P. Ogwang
The prophylactic efficiency of Artemisia annua was first discovered and documented by Patrick Ogwang from Uganda in several scientific papers.1 Patrick Ogwang also developed ARTAVOL® in collaboration with scientists at Makerere University. Artavol is a beverage for malaria prevention at household level: a blend of Artemisia annua (without artemisinin)-avocado powder (Persea americana)-lemon grass (Cymbopogon citratus). In the research conducted by the team, it was found that after eight months of taking the beverage, the subjects did not develop any fevers associated with malaria. Among the study participants, hospital visits for fever related causes fell by 80 per cent as compared to the control subjects. In 2014 the Ministry of Health in Uganda recognized the innovation and awarded the principal investigator for outstanding achievement in research for herbal prevention of malaria. Artavol production currently stands at 6,000 one hundred-gram tins per month.2
{"title":"An unexpected, revolutionary property of Artemisia infusions: immunoglobulins in the skin lead to a longlasting prophylaxis","authors":"P. Lutgen, Jérôme Munyangi, Pascal Gisenya, P. Ogwang","doi":"10.15406/ppij.2020.08.00280","DOIUrl":"https://doi.org/10.15406/ppij.2020.08.00280","url":null,"abstract":"The prophylactic efficiency of Artemisia annua was first discovered and documented by Patrick Ogwang from Uganda in several scientific papers.1 Patrick Ogwang also developed ARTAVOL® in collaboration with scientists at Makerere University. Artavol is a beverage for malaria prevention at household level: a blend of Artemisia annua (without artemisinin)-avocado powder (Persea americana)-lemon grass (Cymbopogon citratus). In the research conducted by the team, it was found that after eight months of taking the beverage, the subjects did not develop any fevers associated with malaria. Among the study participants, hospital visits for fever related causes fell by 80 per cent as compared to the control subjects. In 2014 the Ministry of Health in Uganda recognized the innovation and awarded the principal investigator for outstanding achievement in research for herbal prevention of malaria. Artavol production currently stands at 6,000 one hundred-gram tins per month.2","PeriodicalId":19839,"journal":{"name":"Pharmacy & Pharmacology International Journal","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78664618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-02-11DOI: 10.15406/PPIJ.2020.08.00279
R. Baghirova
In order to elucidate the causes of irreversible changes in the activity of the hippocampus after the destruction of the dorsal amygdalofugal pathway, limbic brain structures (amygdala, hypothalamus, reticular formation) were recorded before and after electrical stimulation and destruction of the dorsal amygdalofugal pathway. The data obtained indicate that a necessary condition in the mechanisms of regulation of the excitability of neurons in various nuclei of the hypothalamus, amygdala and reticular formation is a functional integrity of dorsal amygdalofuqal pathway.
{"title":"Study of the electrical activity of limbic brain structures after the destruction of the dorsal amygdalofugal pathway","authors":"R. Baghirova","doi":"10.15406/PPIJ.2020.08.00279","DOIUrl":"https://doi.org/10.15406/PPIJ.2020.08.00279","url":null,"abstract":"In order to elucidate the causes of irreversible changes in the activity of the hippocampus after the destruction of the dorsal amygdalofugal pathway, limbic brain structures (amygdala, hypothalamus, reticular formation) were recorded before and after electrical stimulation and destruction of the dorsal amygdalofugal pathway. The data obtained indicate that a necessary condition in the mechanisms of regulation of the excitability of neurons in various nuclei of the hypothalamus, amygdala and reticular formation is a functional integrity of dorsal amygdalofuqal pathway.","PeriodicalId":19839,"journal":{"name":"Pharmacy & Pharmacology International Journal","volume":"75 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81714484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-02-10DOI: 10.15406/PPIJ.2020.08.00278
A. Churojana
bleomycin was found to have a local sclerosing effect on vascular endothelium with nonspecific inflammatory reaction and occlusion of vessels. 6‒10 It was first therapeutically used bleomycin solution as a sclerosing agent for cystic hygroma by Jura et al with good outcome in 1977. 15 After that, it came more studies and publications worldwide, with similar success, which was initially in Japan, then in Australia, Turkey, Sweden, China, South Africa and other countries. 6‒10,15‒19 In our center, the procedures have been performed by local or sedative anesthesia, if the lesions are small or superficial location. However, for deep lesions of head and neck, particularly those which affect airway, the procedure must be performed under general anesthesia.
{"title":"Bleomycin: An effective drug for intralesional injection treatment of vascular anomalies","authors":"A. Churojana","doi":"10.15406/PPIJ.2020.08.00278","DOIUrl":"https://doi.org/10.15406/PPIJ.2020.08.00278","url":null,"abstract":"bleomycin was found to have a local sclerosing effect on vascular endothelium with nonspecific inflammatory reaction and occlusion of vessels. 6‒10 It was first therapeutically used bleomycin solution as a sclerosing agent for cystic hygroma by Jura et al with good outcome in 1977. 15 After that, it came more studies and publications worldwide, with similar success, which was initially in Japan, then in Australia, Turkey, Sweden, China, South Africa and other countries. 6‒10,15‒19 In our center, the procedures have been performed by local or sedative anesthesia, if the lesions are small or superficial location. However, for deep lesions of head and neck, particularly those which affect airway, the procedure must be performed under general anesthesia.","PeriodicalId":19839,"journal":{"name":"Pharmacy & Pharmacology International Journal","volume":"125 20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73379400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-02-07DOI: 10.15406/PPIJ.2020.08.00277
D. Fiel, Rita Calça, Eunice Cacheira, Nuno Rombo, S. Querido, C. Nascimento, C. Jorge, A. Weigert, R. Birne, Belarmino Clemente, A. Martinho, C. Toscano, M. Bruges, Beatriz Malvar, D. Machado
Cupriavidus pauculus is a gram-negative aerobic bacillus usually isolated from bottled mineral water, water from ultrafiltration systems in hospital setting and medical devices. Infections in humans are rare but usually severe, with most described cases of bacteremia, pneumonia, meningitis and sepsis. We describe a rare case of a Cupriavidus pauculus infection in a post-kidney-transplant context. A 60-year-old man, with Chronic Kidney Disease due to chronic glomerulonephritis, initiated hemodialysis in 1991 and received a cadaveric-donor kidney transplant in 1997. The graft functioned until 2008, when he returned to hemodialysis. After 2 years, he transited to Peritoneal Dialysis because of vascular access failure. He remained on PD for 7 years and received a new kidney transplant in 2018 after Encapsulating Peritoneal Sclerosis (EPS). The graft never gained function, so he remained peritoneal-dialysis-dependent. A few days after transplantation, peritonitis ensued ( Enteroccocus faecium , Serratia marcescens ). Even after Tenckhoff catheter removal, the clinical condition deteriorated, with need for continuous hemodiafiltration. The diagnose of a cecum perforation was made followed by hemicolectomy. Due to persisting respiratory and abdominal infections despite antibiotic regimens, and no kidney graft function, nephrectomy of the graft was performed, suspending immunosuppressive drugs. Later, a Cupriavidus pauculus was isolated in sputum, confirmed in two samples. Bacterial examination of the dialysis unit water system and equipment as well as of the ventilator used by the patient was negative. To our knowledge, this is the first case of a respiratory tract infection associated with Cupriavidus pauculus described in a post-kidney-transplant patient.
{"title":"Cupriavius pauculus causing a respiratory tract infection in a post-kidney-transplant patient: A firstly described rare clinical case","authors":"D. Fiel, Rita Calça, Eunice Cacheira, Nuno Rombo, S. Querido, C. Nascimento, C. Jorge, A. Weigert, R. Birne, Belarmino Clemente, A. Martinho, C. Toscano, M. Bruges, Beatriz Malvar, D. Machado","doi":"10.15406/PPIJ.2020.08.00277","DOIUrl":"https://doi.org/10.15406/PPIJ.2020.08.00277","url":null,"abstract":"Cupriavidus pauculus is a gram-negative aerobic bacillus usually isolated from bottled mineral water, water from ultrafiltration systems in hospital setting and medical devices. Infections in humans are rare but usually severe, with most described cases of bacteremia, pneumonia, meningitis and sepsis. We describe a rare case of a Cupriavidus pauculus infection in a post-kidney-transplant context. A 60-year-old man, with Chronic Kidney Disease due to chronic glomerulonephritis, initiated hemodialysis in 1991 and received a cadaveric-donor kidney transplant in 1997. The graft functioned until 2008, when he returned to hemodialysis. After 2 years, he transited to Peritoneal Dialysis because of vascular access failure. He remained on PD for 7 years and received a new kidney transplant in 2018 after Encapsulating Peritoneal Sclerosis (EPS). The graft never gained function, so he remained peritoneal-dialysis-dependent. A few days after transplantation, peritonitis ensued ( Enteroccocus faecium , Serratia marcescens ). Even after Tenckhoff catheter removal, the clinical condition deteriorated, with need for continuous hemodiafiltration. The diagnose of a cecum perforation was made followed by hemicolectomy. Due to persisting respiratory and abdominal infections despite antibiotic regimens, and no kidney graft function, nephrectomy of the graft was performed, suspending immunosuppressive drugs. Later, a Cupriavidus pauculus was isolated in sputum, confirmed in two samples. Bacterial examination of the dialysis unit water system and equipment as well as of the ventilator used by the patient was negative. To our knowledge, this is the first case of a respiratory tract infection associated with Cupriavidus pauculus described in a post-kidney-transplant patient.","PeriodicalId":19839,"journal":{"name":"Pharmacy & Pharmacology International Journal","volume":"43 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76679350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-30DOI: 10.15406/PPIJ.2020.08.00276
A. Juszczak, P. Ramos, Wojciech Szczolko, B. Pilawa, B. Stanisz
{"title":"Evaluation of antioxidant properties of angiotensinconverting enzyme inhibitors-interactions with free radicals model examined by EPR spectroscopy","authors":"A. Juszczak, P. Ramos, Wojciech Szczolko, B. Pilawa, B. Stanisz","doi":"10.15406/PPIJ.2020.08.00276","DOIUrl":"https://doi.org/10.15406/PPIJ.2020.08.00276","url":null,"abstract":"","PeriodicalId":19839,"journal":{"name":"Pharmacy & Pharmacology International Journal","volume":"76 1","pages":"25-32"},"PeriodicalIF":0.0,"publicationDate":"2020-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90941524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-28DOI: 10.15406/PPIJ.2020.08.00275
F. Zohora, Sneha Sarwar, Ontora Khatun, Praveen Begum, M. Khatun, M. Ahsan, S. N. Islam
{"title":"Estimation of B-vitamins (B1, B2, B3 and B6) by HPLC in vegetables including ethnic selected varieties of Bangladesh","authors":"F. Zohora, Sneha Sarwar, Ontora Khatun, Praveen Begum, M. Khatun, M. Ahsan, S. N. Islam","doi":"10.15406/PPIJ.2020.08.00275","DOIUrl":"https://doi.org/10.15406/PPIJ.2020.08.00275","url":null,"abstract":"","PeriodicalId":19839,"journal":{"name":"Pharmacy & Pharmacology International Journal","volume":"58 1","pages":"16-23"},"PeriodicalIF":0.0,"publicationDate":"2020-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81571046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-09DOI: 10.15406/PPIJ.2020.08.00274
Julia Aracelly Gonzalez Puertas, M. Duran, J. Durán, E. Manrique, B. Palácio, I. Pereira, E. Caballero, E Cabas
Rheumatoid arthritis (RA) is a condition of multifactorial origin, characterized by inflammation and hyperplasia of the synovial membrane of the diarthrodial joints, predominantly of the hands and feet, in which there is production of autoantibodies, destruction of cartilage and subchondral bone, and it is usually accompanied by systemic manifestations such as nodules, cardiovascular disease and pulmonary involvement. Proper and early management improves the evolution and prognosis of the disease.1 The therapy comprises synthetic and biological disease modifying drugs which have serious side effects and, in the case of biological therapy, represents a potential risk of developing infectious diseases and other effects, associated with their mechanism of action.2 The main objective of this study is the identification of the drug-related problems (DRP) and classification of negative clinical outcome (NCO) according to their Necessity, Effectiveness and Safety of pharmacological therapy, through the implementation of a risk management program that prevents or minimizes these adverse health outcomes of patients with rheumatoid arthritis.
{"title":"Risk management model in patients receiving therapy with biotechnological medications for rheumatoid arthritis in a medical center in Barranquilla, Colombia","authors":"Julia Aracelly Gonzalez Puertas, M. Duran, J. Durán, E. Manrique, B. Palácio, I. Pereira, E. Caballero, E Cabas","doi":"10.15406/PPIJ.2020.08.00274","DOIUrl":"https://doi.org/10.15406/PPIJ.2020.08.00274","url":null,"abstract":"Rheumatoid arthritis (RA) is a condition of multifactorial origin, characterized by inflammation and hyperplasia of the synovial membrane of the diarthrodial joints, predominantly of the hands and feet, in which there is production of autoantibodies, destruction of cartilage and subchondral bone, and it is usually accompanied by systemic manifestations such as nodules, cardiovascular disease and pulmonary involvement. Proper and early management improves the evolution and prognosis of the disease.1 The therapy comprises synthetic and biological disease modifying drugs which have serious side effects and, in the case of biological therapy, represents a potential risk of developing infectious diseases and other effects, associated with their mechanism of action.2 The main objective of this study is the identification of the drug-related problems (DRP) and classification of negative clinical outcome (NCO) according to their Necessity, Effectiveness and Safety of pharmacological therapy, through the implementation of a risk management program that prevents or minimizes these adverse health outcomes of patients with rheumatoid arthritis.","PeriodicalId":19839,"journal":{"name":"Pharmacy & Pharmacology International Journal","volume":"68 1","pages":"11-14"},"PeriodicalIF":0.0,"publicationDate":"2020-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85027105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-07DOI: 10.15406/PPIJ.2020.08.00273
Diana Yisenia Pinzon Fajardo, José Julián López Gutiérrez, Jorge Mario Camacho Carvajal
Fibromyalgia (FM) is a complex and little known disease, health professionals face a pathology with a difficult diagnosis, without a therapeutic target, which causes a high burden of morbidity and costs.1–4 There is no single treatment that has proven effective. Several attempts have been made to elucidate the best ways to diagnose and treat FM, but so far no objective evidence has been found to allow the diagnosis to be made or ruled out.1,5–7 Functional magnetic resonance imaging and biochemical marker tests are not useful because they indicate the existence of pain, but not its cause.8,9 This leads to the diagnosis being controversial because it is based only on subjective criteria, which can cause a misdiagnosis of the disease, since each doctor can give a different interpretation has shown that not all doctors know the criteria from the American College of Rheumatology (ACR) to establish a diagnosis.10–12 This is sometimes because many doctors do not accept FM as a pathology, and consider it as a poor adaptive response to stress or depression, increasing patient frustration and generating poor adherence to medical management, which leads to rupture of the doctor-patient relationship. One of the contradictors of the FM is Dr. Frederick Wolfe, director of the National Data Bank for Rheumatic Diseases and lead author of the 1990 article that first defined the diagnostic guidelines for FM, who considers that it is not a disease if not a physical response to stress, depression and economic and social anxiety. Wolfe said that “some of us in those days thought that we had actually identified a disease, which clearly is not,” “Making people sick, making them sick, was something wrong.” Therefore, FM is considered not It requires no pharmacological treatment and that this has only been driven by the profits produced by the sale and commercialization of some medications as without being clear about how it reduces pain.5,11
纤维肌痛(FM)是一种复杂而鲜为人知的疾病，卫生专业人员面临着难以诊断的病理，没有治疗目标，这造成了高昂的发病率和费用负担。没有一种治疗方法被证明是有效的。已经进行了几次尝试，以阐明诊断和治疗FM的最佳方法，但到目前为止，还没有发现客观证据来诊断或排除FM。1,5 - 7功能磁共振成像和生化标记试验是无用的，因为它们表明疼痛的存在，但不是其原因。8,9这导致诊断存在争议，因为它仅基于主观标准，这可能导致疾病的误诊，因为每个医生都可以给出不同的解释，这表明并非所有医生都知道美国风湿病学会(ACR)的诊断标准。10-12这有时是因为许多医生不接受FM作为一种病理，并认为它是对压力或抑郁的一种较差的适应性反应，增加了患者的挫折感，并产生了对医疗管理的较差依从性，从而导致医患关系的破裂。弗雷德里克·沃尔夫(Frederick Wolfe)博士是风湿病国家数据库(National Data Bank for Rheumatic Diseases)的主任，也是1990年首次定义风湿病诊断指南的文章的主要作者。他认为，如果风湿病不是对压力、抑郁、经济和社会焦虑的身体反应，那就不是一种疾病。沃尔夫说:“当时我们中的一些人认为我们实际上已经确定了一种疾病，但显然不是。”“让人生病，让他们生病，是不对的。”因此，FM被认为不需要药物治疗，这只是由一些药物的销售和商业化所产生的利润所驱动，而不清楚它是如何减轻疼痛的
{"title":"Pharmacological treatment of fibromyalgia","authors":"Diana Yisenia Pinzon Fajardo, José Julián López Gutiérrez, Jorge Mario Camacho Carvajal","doi":"10.15406/PPIJ.2020.08.00273","DOIUrl":"https://doi.org/10.15406/PPIJ.2020.08.00273","url":null,"abstract":"Fibromyalgia (FM) is a complex and little known disease, health professionals face a pathology with a difficult diagnosis, without a therapeutic target, which causes a high burden of morbidity and costs.1–4 There is no single treatment that has proven effective. Several attempts have been made to elucidate the best ways to diagnose and treat FM, but so far no objective evidence has been found to allow the diagnosis to be made or ruled out.1,5–7 Functional magnetic resonance imaging and biochemical marker tests are not useful because they indicate the existence of pain, but not its cause.8,9 This leads to the diagnosis being controversial because it is based only on subjective criteria, which can cause a misdiagnosis of the disease, since each doctor can give a different interpretation has shown that not all doctors know the criteria from the American College of Rheumatology (ACR) to establish a diagnosis.10–12 This is sometimes because many doctors do not accept FM as a pathology, and consider it as a poor adaptive response to stress or depression, increasing patient frustration and generating poor adherence to medical management, which leads to rupture of the doctor-patient relationship. One of the contradictors of the FM is Dr. Frederick Wolfe, director of the National Data Bank for Rheumatic Diseases and lead author of the 1990 article that first defined the diagnostic guidelines for FM, who considers that it is not a disease if not a physical response to stress, depression and economic and social anxiety. Wolfe said that “some of us in those days thought that we had actually identified a disease, which clearly is not,” “Making people sick, making them sick, was something wrong.” Therefore, FM is considered not It requires no pharmacological treatment and that this has only been driven by the profits produced by the sale and commercialization of some medications as without being clear about how it reduces pain.5,11","PeriodicalId":19839,"journal":{"name":"Pharmacy & Pharmacology International Journal","volume":"54 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83200483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-12-23DOI: 10.15406/ppij.2019.07.00272
J. Baptista, Lisete S. Paiva, E. Lima, Madalena Motta
{"title":"The surplus value of Azorean Camellia sinensis flowers as an important contributor affecting the nutraceutical benefits of green tea quality","authors":"J. Baptista, Lisete S. Paiva, E. Lima, Madalena Motta","doi":"10.15406/ppij.2019.07.00272","DOIUrl":"https://doi.org/10.15406/ppij.2019.07.00272","url":null,"abstract":"","PeriodicalId":19839,"journal":{"name":"Pharmacy & Pharmacology International Journal","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80148959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-12-12DOI: 10.15406/ppij.2019.07.00270
Angeliki Tsifi, Ioannis Tsifis, Anatol Vieru, M. Triantafyllou, D. Theodoridis, Stavroula-Panagiota Lontou, M. Mantzourani
Extramedullary hematopoiesis (EMH) functions as a compensatory phenomenon in cases of insufficient bone marrow function and refers to the hematopoiesis that takes place outside the medulla of the bone. It is usually associated with various hematologic disorders, including thalassemia.1–4 Hemoglobin H disease is a type of a-thalassemia consisting of the loss of 3 genes (--/-a) and is often manifested as a mild anemia with thalassemic morphological changes and the existence of erythrocyte inclusions. Hemoglobin H is a tetramer composed of four beta globin chains and a great decrease in alpha chain availability.5 In this hemolytic disorder, splenomegaly may occur, as well as mandibular and bone marrow hyperplasia and pathological fractures. Reported herein is the case of a 64-year-old male who suddenly developed a mild anemia, splenomegaly, monoclonal hypergammaglobulinemia and a paraspinal mass and was admitted to our hospital for further investigation. The patient was eventually diagnosed with hemoglobin H disease with concurrent MGUS. The present case report discusses the diagnostic methods, problems and treatment strategies that were applied and seeks to further examine this uncommon clinical manifestation. Case presentation
{"title":"Paraspinal extramedullary hematopoiesis in alpha-thalassemia with concurrent monoclonal gammopathy of undetermined significance: an uncommon case report","authors":"Angeliki Tsifi, Ioannis Tsifis, Anatol Vieru, M. Triantafyllou, D. Theodoridis, Stavroula-Panagiota Lontou, M. Mantzourani","doi":"10.15406/ppij.2019.07.00270","DOIUrl":"https://doi.org/10.15406/ppij.2019.07.00270","url":null,"abstract":"Extramedullary hematopoiesis (EMH) functions as a compensatory phenomenon in cases of insufficient bone marrow function and refers to the hematopoiesis that takes place outside the medulla of the bone. It is usually associated with various hematologic disorders, including thalassemia.1–4 Hemoglobin H disease is a type of a-thalassemia consisting of the loss of 3 genes (--/-a) and is often manifested as a mild anemia with thalassemic morphological changes and the existence of erythrocyte inclusions. Hemoglobin H is a tetramer composed of four beta globin chains and a great decrease in alpha chain availability.5 In this hemolytic disorder, splenomegaly may occur, as well as mandibular and bone marrow hyperplasia and pathological fractures. Reported herein is the case of a 64-year-old male who suddenly developed a mild anemia, splenomegaly, monoclonal hypergammaglobulinemia and a paraspinal mass and was admitted to our hospital for further investigation. The patient was eventually diagnosed with hemoglobin H disease with concurrent MGUS. The present case report discusses the diagnostic methods, problems and treatment strategies that were applied and seeks to further examine this uncommon clinical manifestation. Case presentation","PeriodicalId":19839,"journal":{"name":"Pharmacy & Pharmacology International Journal","volume":"16 1","pages":"315-317"},"PeriodicalIF":0.0,"publicationDate":"2019-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75727850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：